I don't believe there is a TO now Rynzn.
Dr Gittleson is on board to guide the PLATFORM strategy...medium term horizon.
The Boards job is to maximise shareholder value.
How do they do that?
By getting 3 or 4 non-DMD products into clinical development with Big Pharma.
Having said that ...Sarepta are desperate and have big hitter Funds on their register!
A cash + scrip offer may surprise - highly unlikely imo.
.
Where others have failed will Atl1102 succeed ?, page-746
-
- There are more pages in this discussion • 351 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |